Adagene, Inc. (ADAG) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.45

From 52W high−30.75%

Volume286984.00

Market cap$222.24M

P/E (TTM)—

P/S (TTM)23.9x

Div yield—

Key dataSep 18, 2026

Open

$3.45

From 52W high

−30.75%

Volume

286984.00

Market cap

$222.24M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

P/E (TTM)

—

RSI (14)

41.8

MomentumView details →

1D Return

−1.78%

YTD Return

+72.31%

SummaryUpdated Jun 1, 2026

Adagene Inc. (NASDAQ:ADAG) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Suzhou, China. The company went public on February 9, 2021, and focuses on developing innovative monoclonal antibody therapies for cancer treatment. Adagene specializes in creating next-generation antibody drugs using proprietary platforms to address limitations of existing cancer immunotherapies. The company operates primarily in the oncology space, developing treatments for both solid tumors and blood cancers.

Ask drillr about Adagene, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.4x

EV/Sales

12.6x

P/S (TTM)

23.9x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

94.22%

Net Margin

−220.66%

EBITDA Margin

−234.52%

ROE (TTM)

−19.39%

ROA (TTM)

−15.39%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−6.19%

EPS CAGR 3Y

+51.58%

EBITDA YoY

—

MomentumView details →

1D Return

−1.78%

YTD Return

+72.31%

1Y Return

+58.86%

RSI (14)

41.8

vs 50D SMA

−11.45%

vs 200D SMA

−0.97%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

5.02x

Quick Ratio

5.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.23

EPS Surprise

0.00%

Beats (12Q)

3/12

Next Q EPS Est

−$0.74

Avg Surprise (4Q)

15.09%

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

9.42M

Net Income (TTM)

−58.99M

Op. CF (TTM)

−53.47M

Next earningsMar 31, 2027 →

Latest newsMore news →

Third Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene for the development of masked CD3 T cell engagers utilizing Adagene's SAFEbody technology.10d ago

Similar companies

Keros Therapeutics, Inc.KROS Invivyd, Inc.IVVD NervGen Pharma Corp. Common stockNGEN Anavex Life Sciences Corp.AVXL Immunotech Biopharm Ltd06978.HK Alector, Inc.ALEC Find similar companies →

Latest newsMore news →

Third Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene for the development of masked CD3 T cell engagers utilizing Adagene's SAFEbody technology.10d ago